0001127602-17-026938.txt : 20170905
0001127602-17-026938.hdr.sgml : 20170904
20170905153734
ACCESSION NUMBER: 0001127602-17-026938
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170831
FILED AS OF DATE: 20170905
DATE AS OF CHANGE: 20170905
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Babu Yarlagadda S
CENTRAL INDEX KEY: 0001452635
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23186
FILM NUMBER: 171068619
MAIL ADDRESS:
STREET 1: 2190 PARKWAY LAKE DR
CITY: BIRMINGHAM
STATE: AL
ZIP: 35244
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000882796
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 621413174
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4505 EMPEROR BOULEVARD
STREET 2: SUITE 200
CITY: DURHAM
STATE: NC
ZIP: 27703
BUSINESS PHONE: 919-859-1302
MAIL ADDRESS:
STREET 1: 4505 EMPEROR BOULEVARD
STREET 2: SUITE 200
CITY: DURHAM
STATE: NC
ZIP: 27703
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2017-08-31
0000882796
BIOCRYST PHARMACEUTICALS INC
BCRX
0001452635
Babu Yarlagadda S
4505 EMPEROR BLVD.
SUITE 200
DURHAM
NC
27703
1
Senior VP - Drug Discovery
Emp. Stock Option (Right to Buy)
11.13
2017-08-31
4
A
0
27000
0
A
2017-08-31
2024-12-22
Common Stock
27000
27000
D
On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded in December 2014 to all employees, excluding the Chief Executive Officer, has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017.
/s/ Alane P. Barnes, by power of attorney
2017-09-05